ation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 0000 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, 